Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-10-25FDA Approved: OLANZAPINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved the Original Application for olanzapine from Torrent Pharmaceuticals Limited, marking the introduction of a generic olanzapine …
-
CLINICAL_TRIALS research · 2011-10-25Clinical Trial Update: High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia [Phase 2]
An update on a Phase 2 trial examining high-dose D-serine as an adjuvant treatment for recent-onset schizophrenia. The current status of the…
-
CLINICAL_TRIALS trial_result · 2011-10-24Clinical Trial Update: Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients [Phase 4]
A Phase 4 clinical trial evaluating quetiapine's effects on neuroplasticity in patients with first-episode schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2011-10-24Clinical Trial Update: Seroquel XR in the Long Term Treatment of Schizophrenia
A completed clinical trial evaluated quetiapine extended-release (Seroquel XR) for long-term treatment of schizophrenia to reduce relapse ri…
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Sandoz Inc)
FDA approved the Original Application for olanzapine from Sandoz Inc., making a generic olanzapine available (ANDA 201588).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Dr. Reddy's Laboratories Ltd.)
FDA approved an original generic application for olanzapine from Dr. Reddy's Laboratories Ltd.
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original ANDA for generic olanzapine (olanzapine tablets). The product is indicated for schizophrenia and bipola…
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Dr.Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories Limited's original application for a generic olanzapine product (ANDA076534), enabling market entry of…
-
FDA approval · 2011-10-19FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2011-10-17Clinical Trial Update: Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study [Phase 2]
Phase 2 clinical trial update of a GABA-A Alpha2/3 selective agent in schizophrenia; results have been posted.
-
CLINICAL_TRIALS trial_result · 2011-10-14Clinical Trial Update: NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
A clinical trial update from AstraZeneca reports monitoring improvement in Global Assessment of Functioning in patients with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2011-10-06Clinical Trial Update: Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia [Phase 3]
This document reports the results of a long-term safety Phase 3 study of lurasidone in clinically stable schizophrenia and schizoaffective d…
-
CLINICAL_TRIALS trial_result · 2011-10-06Clinical Trial Update: Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. [Phase 3]
Results from a 6-week Phase 3 trial of lurasidone hydrochloride for acute schizophrenia have been posted.
-
CLINICAL_TRIALS trial_result · 2011-10-06Clinical Trial Update: Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia [Phase 2, Phase 3]
A Phase 2/Phase 3 study evaluating a neurocognition enhancing agent for schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2011-10-04Clinical Trial Update: Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia [Phase 3]
A Phase 3 head-to-head trial comparing paliperidone palmitate with RISPERDAL CONSTA in adults with schizophrenia has completed, with results…
-
FDA approval · 2011-09-27FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for haloperidol decanoate from Hikma Pharmaceuticals USA Inc., updating the approved generic long-ac…
-
FDA approval · 2011-09-27FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for haloperidol decanoate from Fresenius Kabi USA, LLC. This action relates to continued approval of…
-
FDA approval · 2011-09-27FDA Approved: RISPERIDONE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for risperidone, granting approval of a generic risperidone product. This is …
-
FDA approval · 2011-09-26FDA Approved: LOXAPINE — Original Application (Lannett Company, Inc.)
The FDA approved the original application for LOXAPINE from Lannett Company, Inc., providing a generic loxapine product. Loxapine is an anti…
-
FDA approval · 2011-09-24FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved Janssen's supplemental application for Risperdal M-TAB (risperidone), adding the M-TAB dosage form to the approved product.…
-
FDA approval · 2011-09-24FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) submitted by Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2011-09-23Clinical Trial Update: Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia
A completed non-interventional, open-label study evaluating the effect of Quetiapine XR on patient satisfaction and quality of life in peopl…
-
CLINICAL_TRIALS trial_result · 2011-09-20Clinical Trial Update: The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia [Phase 2]
The CAMPUS Project, a Phase 2 trial evaluating cholinergic augmentation of cognitive deficits in schizophrenia, has been terminated.
-
CLINICAL_TRIALS trial_result · 2011-09-19Clinical Trial Update: Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia [NA]
This entry reports the completion of a clinical trial examining dopaminergic, functional, structural, and cognitive disturbances in individu…
-
CLINICAL_TRIALS research · 2011-09-19Clinical Trial Update: Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia [NA]
This document provides an update on a completed clinical trial investigating neurobiological and neurocognitive disturbances in individuals …